Catabasis Pharma's CAT-1004 Fast Track'd for DMD
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 7:25AM CDT
CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), CATB: 14.38 (+1.83), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
EMA accepts BioMarin's MAA for drisapersen; marketing clearance possible in Q3 2016
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:32PM CDT
CAPR: 4.70 (-0.06), RNA: 18.65 (unch), CATB: 14.38 (+1.83), PFE: 34.36 (+0.50), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
Akashi Therapeutics' Duchenne MD candidate shows encouraging results in early stage study
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 9:48AM CDT
CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), CATB: 14.38 (+1.83), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
Catabasis Pharma initiates Phase 1/2 study of DMD candidate
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 9:45AM CDT
CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), CATB: 14.38 (+1.83), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
FDA publishes draft guidance for firms developing Duchenne muscular dystrophy drugs; current front-runners OK
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 12:07PM CDT
BMRN: 141.67 (+1.54), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75)
Capricor Therapeutics jumps on FDA OK for DMD study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 8:41AM CDT
ROSG: 3.20 (+0.06), CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), PFE: 34.36 (+0.50), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
Sarepta to initiate rolling NDA submission for eteplirsen; shares jump 38%
Seeking Alpha - at Seeking Alpha - Tue May 19, 4:40PM CDT
ROSG: 3.20 (+0.06), CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), PFE: 34.36 (+0.50), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 3.20 (+0.06), CAPR: 4.70 (-0.06), BMRN: 141.67 (+1.54), RNA: 18.65 (unch), PFE: 34.36 (+0.50), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 388.23 (-11.06), VRTX: 122.95 (+2.06), PRGO: 180.86 (+0.85), PFE: 34.36 (+0.50), CLDN: 1.26 (+0.01), MYL: 71.22 (+0.87), OREX: 4.70 (+0.04), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), TNXP: 8.22 (-0.36), ALNY: 121.77 (+5.73), GILD: 113.74 (+0.38), SGEN: 47.09 (+0.57), ACHN: 8.68 (+0.14), MRK: 57.95 (+0.57), GALE: 1.63 (+0.10), JUNO: 52.05 (+1.72), SNY: 51.49 (+2.71), NBY: 0.62 (+0.01), XLRN: 30.03 (+0.20)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 141.67 (+1.54), SRPT: 30.02 (+0.66), PTCT: 46.49 (+1.75)